New triple therapy aims to control liver-metastatic colorectal cancer in late-stage patients

NCT ID NCT07353268

First seen Jan 31, 2026 · Last updated May 12, 2026 · Updated 8 times

Summary

This study tests whether a new combination of an antibody drug (QL1706), a targeted therapy (fruquintinib), and short-course radiotherapy can help control advanced colorectal cancer that has spread to the liver and hasn't responded to earlier treatments. About 76 adults aged 18 to 75 with a specific type of colorectal cancer (pMMR/MSS) will be enrolled. The goal is to see if this approach is safer and more effective than standard third-line therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.